The Non Invasive Cancer Diagnostics Market Is Projected To Grow At An Annualized Rate Of ~20%, Till

Posted on by Admin

Roots Analysis has done a detailed study on Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 350+ page report, which features 150+ figures and 200+ tables, please visit this link

Key Market Insights

  • Presently, nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world
  • Several modern diagnostic tests claim to be capable of offering results in relatively short time periods, thereby, facilitating early diagnosis that is particularly beneficial in the treatment of different types of cancers
  • Over time, big pharma players have initiated product development programs, having invested significant capital, time and effort, on non-invasive diagnostic solutions for use across different oncological indications
  • Investors, having realized the untapped opportunity within this emerging segment of the cancer diagnostics market, have invested over USD 3 billion across 120 instances in the period between 2015 and 2019
  • The growing interest in this field is also reflected in the partnership activity; deals inked in the recent past are focused on a diverse range of tumor markers, involving both international and indigenous stakeholders
  • The projected future opportunity is anticipated to be driven by increasing patient population and distributed across various disease indications and application areas across key geographies
  • These tests are capable of detecting diverse tumor markers that cater to the needs of different stakeholders; in fact, opinions of industry experts confirm the vast potential of liquid biopsies in disease diagnosis / monitoring

For more information, please visit

Table of Contents

  1. PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

  1. EXECUTIVE SUMMARY
  1. INTRODUCTION

3.1. Chapter Overview

3.2. Cancer Statistics and Burden of the Disease

3.3. Importance of Early Cancer Detection

3.4. Cancer Screening and Diagnosis

3.5. Conventional Invasive Cancer Diagnostic Tests

3.5.1. Biopsy

3.5.1.1. Fine Needle Aspiration Biopsy

3.5.1.2. Core Needle Biopsy

3.5.1.3. Vacuum-Assisted Biopsy

3.5.1.4. Image-Guided Biopsy

Press Release: Variation 2 (Format 3)

3.5.1.5. Sentinel Node Biopsy

3.5.1.6. Surgical Biopsy

3.5.1.7. Endoscopic Biopsy

3.5.1.8. Bone Marrow Biopsy

3.5.2. Endoscopy

3.6. Need for Non-Invasive Approaches

3.7. Liquid Biopsy: Diagnosing Circulating Biomarkers

3.7.1. Circulating Tumor Cells

3.7.2. Circulating Tumor DNA

3.7.3. Exosomes

3.8. Costs and Benefits Associated with Liquid Biopsy and Non-Invasive Tests

3.9. Emerging Trends in Intellectual Property Related to Non-Invasive Cancer Diagnostics

3.10. Challenges Associated with Non-Invasive Cancer Diagnostics

3.11. Future Perspectives

  1. NON-INVASIVE CANCER SCREENING AND DIAGNOSIS

4.1. Chapter Overview

4.2. Diagnostic Imaging

4.2.1. Magnetic Resonance Imaging (MRI)

4.2.2. Mammography

4.2.3. Bone Scan

4.2.4. Computerized Tomography (CT) Scan

4.2.5. Integrated Positron Emission Tomography (PET)-CT Scan

4.2.6. Ultrasound

4.2.7. X-ray Radiography (Barium Enema)

4.3. Screening Assays

4.3.1. Circulating Tumor Marker Test

4.3.2. Digital Rectal Exam (DRE)

4.3.3. Fecal Occult Blood Test (FOBT)

4.3.4. Multigated Acquisition (MUGA) Scan

4.3.5. Papanicolaou Test and Human Papilloma Virus Test

4.4. Advanced Non-Invasive Approaches

4.4.1. Cytogenetic / Gene Expression Studies

4.4.2. Molecular Signature-based Non-Invasive Methods

4.4.3. Saliva-based Oral Cancer Diagnostics

4.4.4. Vital Staining

4.4.5. Optical Biopsy

4.4.6. Other Diagnostic Techniques

  1. MARKET LANDSCAPE

5.1. Chapter Overview

5.2. Liquid Biopsy Products: List of Developers

5.2.1. Analysis by Year of Establishment

5.2.2. Analysis by Company Size and Geographical Location

5.2.3. Leading Players

5.2.4. Analysis by Geography

5.3. Liquid Biopsy Products: List of Available / Under Development Products

5.3.1. Analysis by Status of Development

5.3.2. Analysis by Type of Product

5.3.3. Analysis by Application Area

Press Release: Variation 2 (Format 3)

5.3.4. Analysis by Target Cancer Indication

5.3.5. Analysis by Type of Tumor Marker

5.3.6. Analysis by End User

5.3.7. Analysis by Turnaround Time

5.4. Liquid Biopsy Products: List of Other Products, Kits and Consumables

5.5. Liquid Biopsy Products: List of Contract Service Providers

  1. COMPANY PROFILES

6.1. Chapter Overview

6.2. Amoy Diagnostics

6.2.1. Company Overview

6.2.2. Financial Information

6.2.3. Liquid Biopsy Product Portfolio

6.2.4. Recent Developments and Future Outlook

6.3. DiaCarta

6.3.1. Company Overview

6.3.2. Liquid Biopsy Product Portfolio

6.3.3. Recent Developments and Future Outlook

6.4. HaploX

6.4.1. Company Overview

6.4.2. Liquid Biopsy Product Portfolio

6.4.3. Recent Developments and Future Outlook

6.5. NeoGenomics

6.5.1. Company Overview

6.5.2. Financial Information

6.5.3. Liquid Biopsy Product Portfolio

6.5.4. Recent Developments and Future Outlook

6.6. QIAGEN

6.6.1. Company Overview

6.6.2. Financial Information

6.6.3. Liquid Biopsy Product Portfolio

6.6.4. Recent Developments and Future Outlook

6.7. Swift Biosciences

6.7.1. Company Overview

6.7.2. Liquid Biopsy Product Portfolio

6.7.3. Recent Developments and Future Outlook

6.8. Sysmex Inostics

6.8.1. Company Overview

6.8.2. Liquid Biopsy Product Portfolio

6.8.3. Recent Developments and Future Outlook

6.9. Thermo Fisher Scientific

6.9.1. Company Overview

6.9.2. Financial Information

6.9.3. Liquid Biopsy Product Portfolio

6.9.4. Recent Developments and Future Outlook

  1. PARTNERSHIPS AND COLLABORATIONS

7.1. Chapter Overview

Press Release: Variation 2 (Format 3)

7.2. Partnership Models

7.3. List of Partnerships and Collaborations

7.3.1. Analysis by Year of Partnership

7.3.2. Analysis by Type of Partnership

7.3.3. Analysis by Type of Tumor Marker

7.3.4. Analysis by Target Cancer Indication

7.3.5. Analysis by Type of Partner

7.3.6. Most Active Players: Analysis by Number of Partnerships

7.3.7. Regional Analysis

7.3.7.1. Intercontinental and Intracontinental Agreements

  1. FUNDING AND INVESTMENT ANALYSIS

8.1. Chapter Overview

8.2. Types of Funding

8.3. List of Funding and Investment Instances

8.3.1. Analysis by Number of Funding Instances

8.3.2. Analysis by Amount Invested

8.3.3. Analysis by Type of Funding

8.3.4. Analysis by Target Cancer Indication

8.3.5. Analysis by Type of Tumor Marker

8.3.6. Most Active Players: Analysis by Amount Invested

8.3.7. Most Active Investors: Analysis by Number of Funding Instances

8.3.8. Regional Analysis by Amount Invested

8.4. Concluding Remarks

  1. LIQUID BIOPSY: INITIATIVES OF BIG PHARMA PLAYERS

9.1. Chapter Overview

9.2. Top Pharmaceutical Companies

9.2.1. Analysis by Status of Development

9.2.2. Analysis by Type of Tumor Marker

9.2.3. Analysis by Application Area

9.2.4. Analysis by Target Cancer Indication

  1. KEY ACQUISITION TARGETS

10.1. Chapter Overview

10.2. Scope and Methodology

10.3. Scoring Criteria and Key Assumptions

10.4. Potential Strategic Acquisition Targets in North America

10.5. Potential Strategic Acquisition Targets in Europe

10.6. Potential Strategic Acquisition Targets in Asia-Pacific / Rest of the World

10.7. Concluding Remarks

  1. OTHER NON-INVASIVE CANCER DIAGNOSTICS

11.1. Chapter Overview

11.2. Non-Blood-based Biomarker Detection Tests

11.3. FOBT and Fecal Immunochemical Tests (FIT)

11.4. Pigmented Lesion Assays

11.5. Stool DNA (sDNA)-based Tests

11.6. Volatile Organic Compound (VOC) Detection Tests

11.7. Other Non-Invasive Cancer Diagnostics: Market Landscape

  1. MARKET SIZING AND OPPORTUNITY ANALYSIS

12.1. Chapter Overview

12.2. Key Assumptions and Forecast Methodology

Press Release: Variation 2 (Format 3)

12.3. Global Non-Invasive Cancer Diagnostics Market, 2019-2030

12.3.1. Global Liquid Biopsy Market, 2019-2030

12.3.1.1. Global Liquid Biopsy Market: Distribution by Application Area, 2019-2030

12.3.1.1.1. Global Liquid Biopsy Market for Early Diagnosis, 2019-2030

12.3.1.1.2. Global Liquid Biopsy Market for Patient Monitoring, 2019-2030

12.3.1.1.3. Global Liquid Biopsy Market for Recurrence Monitoring, 2019-2030

12.3.1.2. Global Liquid Biopsy Market: Distribution by Target Cancer Indication, 2019-2030

12.3.1.2.1. Global Liquid Biopsy Market for Breast Cancer, 2019-2030

12.3.1.2.2. Global Liquid Biopsy Market for Lung Cancer, 2019-2030

12.3.1.2.3. Global Liquid Biopsy Market for Colorectal Cancer, 2019-2030

12.3.1.2.4. Global Liquid Biopsy Market for Prostate Cancer, 2019-2030

12.3.1.2.5. Global Liquid Biopsy Market for Bladder Cancer, 2019-2030

12.3.1.2.6. Global Liquid Biopsy Market for Melanoma, 2019-2030

12.3.1.2.7. Global Liquid Biopsy Market for Gastric Cancer, 2019-2030

12.3.1.2.8. Global Liquid Biopsy Market for Pancreatic Cancer, 2019-2030

12.3.1.2.9. Global Liquid Biopsy Market for Ovarian Cancer, 2019-2030

12.3.1.3. Global Liquid Biopsy Market: Distribution by Type of Tumor Marker, 2019-2030

12.3.1.3.1. Global Liquid Biopsy Market for ctDNA, 2019-2030

12.3.1.3.2. Global Liquid Biopsy Market for cfDNA, 2019-2030

12.3.1.3.3. Global Liquid Biopsy Market for CTCs, 2019-2030

12.3.1.3.4. Global Liquid Biopsy Market for Exosomes, 2019-2030

12.3.1.3.5. Global Liquid Biopsy Market for Other Tumor Markers, 2019-2030

12.3.1.4. Global Liquid Biopsy Market: Distribution by Type of Analyte, 2019-2030

12.3.1.4.1. Global Liquid Biopsy Market for Blood, 2019-2030

12.3.1.4.2. Global Liquid Biopsy Market for Other Body Fluids, 2019-2030 (USD Billion)

12.3.1.5. Global Liquid Biopsy Market: Distribution by End User, 2019-2030

12.3.1.5.1. Global Liquid Biopsy Market for Hospitals, 2019-2030

12.3.1.5.2. Global Liquid Biopsy Market for Research Institutes, 2019-2030

12.3.1.5.3. Global Liquid Biopsy Market for Other End Users, 2019-2030

12.3.1.6. Global Liquid Biopsy Market: Distribution by Geography, 2019-2030

12.3.1.6.1. Liquid Biopsy Market in the US, 2019-2030

12.3.1.6.2. Liquid Biopsy Market in the UK, 2019-2030

12.3.1.6.3. Liquid Biopsy Market in Germany, 2019-2030

12.3.1.6.4. Liquid Biopsy Market in France, 2019-2030

12.3.1.6.5. Liquid Biopsy Market in Italy, 2019-2030

12.3.1.6.6. Liquid Biopsy Market in Spain, 2019-2030

12.3.1.6.7. Liquid Biopsy Market in Japan, 2019-2030

12.3.1.6.8. Liquid Biopsy Market in China, 2019-2030

12.3.1.6.9. Liquid Biopsy Market in India, 2019-2030

12.3.1.6.10. Liquid Biopsy Market in Australia, 2019-2030

12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2019-2030

  1. SURVEY INSIGHTS

13.1. Chapter Overview

13.2. Company Specifics of Respondents

13.3. Designation of Respondents

13.4. Type of Product Portfolio

13.5. Types of Products / Services Offered

13.6. Application Area

Press Release: Variation 2 (Format 3)

13.7. Status of Development of the Products

13.8. Likely Market Size

  1. CONCLUSION

14.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care

in the Field of Oncology

14.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer

Management

14.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis

14.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range

of Applications

14.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different

Geographies

14.6. In Addition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further

Strengthen the Ongoing Innovation

14.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential

14.8. Primarily Led by Liquid Biopsy, the Non-Invasive Cancer Diagnostics Market has Emerged

as a Multi-Billion Dollar Market

  1. EXECUTIVE INSIGHTS

15.1. Chapter Overview

15.2. Interview Transcript: Shibichakravarthy Kannan, Founder & Chief Executive Officer,

Theranosis Life Sciences

15.3. Interview Transcript: Anton Iliuk, President and Chief Technology Officer, Tymora Analytical

Operations

15.4. Interview Transcript: Peter French, Strategic Technology Advisor, Sienna Cancer

Diagnostics

15.5. Interview Transcript: Joachim Fluhrer, Founder and Medical Director, Genostics

15.6. Interview Transcript: Brad Walsh, Chief Executive Officer, Minomic International

15.7. Interview Transcript: Catalina Vasquez, Chief Operating Officer, Nanostics

15.8. Interview Transcript: Burkhard Jansen, Chief Medical Officer, DermTech

15.9. Interview Transcript: Frank Szczepanski, President and CEO, IVDiagnostics

15.10. Interview Transcript: Riccardo Razzini, Sales and Marketing Manager, LCM Genect

15.11. Interview Transcript: Nathalie Bernard, Marketing Director, OncoDNA

15.12. Interview Transcript: Abizar Lakdawalla, Founder, Proxeom

15.13. Interview Transcript: Mark Li, CEO, Resolution Bioscience

15.14. Interview Transcript: Christer Ericsson, Chief Scientific Officer, iCellate Medical

15.15. Interview Transcript: Philippe Nore, CEO and Co-founder, MiNDERA

15.16. Interview Transcript: Jake Micallef, Chief Scientific Officer, VolitionRx

  1. APPENDIX 1: TABULATED DATA
  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com